virusPHIX+

  • Inactivates all tested viruses and bacteria, including SARS-CoV-2, Zika, Dengue, m.tuberculosis, and Influenza
  • Long term RNA stabilisation at room temperature
  • Free from guanidine and other toxic chemicals
  • Suitable for swab and saliva testing

 

SARS-CoV-2 inactivation in 10 minutes

A recent study from the Roslin Institute in Edinburgh, UK concluded that virusPHIX+™ inactivates SARS-CoV-2 in as little as 10 minutes when treated at a 1:1 sample to reagent ratio at room temperature. Under these conditions, a 10log6 reduction in SARS-CoV-2 virus titre was recorded.

1 month stabilisation of SARS-CoV-2 at room temperature

Independent study by Qnostics UK demonstrated that virusPHIX+™ stabilises SARS-CoV-2 virus RNA for at least 33 days at 20°C. Sputum samples spiked with SARS-CoV-2 RNA were analysed over 33 days, and the Ct value was compared with virusPHIX+™ treated samples and control (no stabiliser added) – see below data.

Cat. Number: RD-VRP-50 Category:

    Product

    Sku

    Name (required)

    Country (required)

    Company

    Email (required)

    Message

    Description

    SARS-CoV-2 inactivation in 10 minutes

    A recent study from the Roslin Institute in Edinburgh, UK concluded that virusPHIX+™ inactivates SARS-CoV-2 in as little as 10 minutes when treated at a 1:1 sample to reagent ratio at room temperature. Under these conditions, a 10log6 reduction in SARS-CoV-2 virus titre was recorded.

    1 month stabilisation of SARS-CoV-2 at room temperature

    Independent study by Qnostics UK demonstrated that virusPHIX+™ stabilises SARS-CoV-2 virus RNA for at least 33 days at 20°C. Sputum samples spiked with SARS-CoV-2 RNA were analysed over 33 days, and the Ct value was compared with virusPHIX+™ treated samples and control (no stabiliser added).

    Data kindly provided by Qnostics, UK.

     

    Public Health England SARS-CoV-2 Inactivation Study

    As part of PHE’s analysis of a number of viral transport mediums, PHE evaluated inactivation of SARS-CoV-2 with virusPHIX+™.
    Triplicate samples of tissue culture fluid containing 5% (v/v) foetal calf serum, spiked with SARS-CoV-2 were treated with virusPHIX+™ for indicated contact time/s or mock-treated in triplicate with an equivalent volume of PBS. All samples were then subjected to a purification step to remove cytotoxic buffer components. PBS-treated samples were subjected to the same purification procedure in parallel.

    Test 1: Purified samples were immediately titrated on Vero E6 cells to establish virus titre. This test is quantitative and reports the titre of virus in each treatment condition in TCID50 per ml. Reduction in virus titre following treatment is given as the difference between the mean log10 TCID50/ml for treated conditions and the PBS control.

    Test 2: In parallel, purified samples were seeded onto Vero E6 monolayers to amplify any remaining virus over the course of up to four serial passages. Virus amplification over each passage was detected by visual (microscopic) examination of monolayers for cytopathic effect, and confirmed by SARS-CoV-2-specific real-time PCR. This test is qualitative and reports either the presence or absence of virus amplification. This test may detect levels of virus that are below the detection limit of the titration assay (test 1) due to a greater sample plating volume and the opportunity for any virus present to amplify over serial passages:

    View the study here: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/937439/HCM-CoV2-034-v2_virusPHIX_TCF__5_.pdf